Related Articles by Review for PMID: 20054396

Year	Number of Results
2010	4
2013	2
2014	2
2015	2
2016	1
2017	1
2018	2
2019	1
2020	2
2021	4
2022	6
2023	5
2024	1

1

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Davis RE, et al. Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638. Nature. 2010. PMID: 20054396 Free PMC article.

2

B-cell receptor signaling as a driver of lymphoma development and evolution.

Niemann CU, Wiestner A. Niemann CU, et al. Semin Cancer Biol. 2013 Dec;23(6):410-21. doi: 10.1016/j.semcancer.2013.09.001. Epub 2013 Sep 20. Semin Cancer Biol. 2013. PMID: 24060900 Free PMC article. Review.

3

B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.

Seda V, Mraz M. Seda V, et al. Eur J Haematol. 2015 Mar;94(3):193-205. doi: 10.1111/ejh.12427. Epub 2014 Sep 13. Eur J Haematol. 2015. PMID: 25080849 Review.

4

Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.

Knittel G, Liedgens P, Korovkina D, Pallasch CP, Reinhardt HC. Knittel G, et al. Eur J Haematol. 2016 Dec;97(6):499-510. doi: 10.1111/ejh.12792. Epub 2016 Sep 8. Eur J Haematol. 2016. PMID: 27526684 Review.

5

B-cell receptor signaling in diffuse large B-cell lymphoma.

Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM. Young RM, et al. Semin Hematol. 2015 Apr;52(2):77-85. doi: 10.1053/j.seminhematol.2015.01.008. Epub 2015 Jan 15. Semin Hematol. 2015. PMID: 25805587 Free PMC article. Review.

6

Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.

Fontán L, Melnick A. Fontán L, et al. Clin Cancer Res. 2013 Dec 15;19(24):6662-8. doi: 10.1158/1078-0432.CCR-12-3869. Epub 2013 Sep 4. Clin Cancer Res. 2013. PMID: 24004675 Review.

7

Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.

Smith CIE, Burger JA. Smith CIE, et al. Front Immunol. 2021 Jun 10;12:689472. doi: 10.3389/fimmu.2021.689472. eCollection 2021. Front Immunol. 2021. PMID: 34177947 Free PMC article. Review.

8

B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells.

Tkachenko A, Kupcova K, Havranek O. Tkachenko A, et al. Int J Mol Sci. 2023 Dec 19;25(1):10. doi: 10.3390/ijms25010010. Int J Mol Sci. 2023. PMID: 38203179 Free PMC article. Review.

9

MYD88^L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.

Chen R, Zhou D, Wang L, Zhu L, Ye X. Chen R, et al. Ther Adv Hematol. 2022 Jan 31;13:20406207211072839. doi: 10.1177/20406207211072839. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35126963 Free PMC article. Review.

10

The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.

Xu PP, Shen R, Shi ZY, Cheng S, Wang L, Liu Y, Zhang L, Huang R, Ma X, Wu X, Yao H, Yu Y, Zhao WL. Xu PP, et al. Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):e1051-e1058.e1. doi: 10.1016/j.clml.2022.08.006. Epub 2022 Aug 20. Clin Lymphoma Myeloma Leuk. 2022. PMID: 36182550 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

28 results

Results by year